TargetBeta
F11
coagulation factor XI · also FXI · Serine proteases
3 programs in company-led studies act on F11, from 3 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| abelacimab | Anthos Therapeutics | inhibitor | phase 3 | 83 running | – | the company's pipeline |
| milvexian | Bristol-Myers Squibb | inhibitor | phase 3 | 252 running | – | a judged reading |
| SHR-2004 | Jiangsu HengRui Medicine | – | phase 3 | 50 running | – | the company's pipeline |
Conditions their studies are in
- Atrial Fibrillation, 3 programs
- Venous Thromboembolism, 2 programs
- Acute Coronary Syndrome, 1 program
- Ischemic Stroke, 1 program
- Ovarian Neoplasms, 1 program
- Stroke, 1 program
- Thrombosis, 1 program
- Venous Thrombosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 8, 2026milvexian · Bristol-Myers Squibb · phase 3 · NCT05757869
- Dec 30, 2027abelacimab · Anthos Therapeutics · phase 3 · NCT05712200
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.